Tweet
Conclusion
The present study applied a novel method – intra-MG injection of the antivascularization agent bevacizumab – as an MGD therapy, and demonstrated that the treatment is effective and safe in eliminating eyelid-margin vascularity, improving MG function, and relieving clinical signs and symptoms of MGD.
The present study applied a novel method – intra-MG injection of the antivascularization agent bevacizumab – as an MGD therapy, and demonstrated that the treatment is effective and safe in eliminating eyelid-margin vascularity, improving MG function, and relieving clinical signs and symptoms of MGD.
"Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity"
it was find in the blog of dr Sandra lora Cemers see:
https://eyedoc2020.blogspot.com/2018...-was-kind.html
Comment